<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02963038</url>
  </required_header>
  <id_info>
    <org_study_id>SenL_19</org_study_id>
    <nct_id>NCT02963038</nct_id>
  </id_info>
  <brief_title>CAR T Cells for Refractory B Cell Malignancy</brief_title>
  <official_title>Autologous CD19-targeting CAR T Cells for Refractory B Cell Malignancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Senlang Biotechnology Inc., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Second Hospital of Hebei Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hebei Senlang Biotechnology Inc., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chimeric antigen receptor (CAR) T cells targeting CD19 will be evaluated for safety and
      efficacy in patients with B cell malignancy including lymphoma or leukemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The CAR consists of a CD19 targeting antibody scFv with three intracellular signaling domains
      derived from CD3 zeta, CD28 and 4-1BB. Autologous T cells will be gene engineered with the
      CAR gene using a lentivirus vector. Prior to T cell infusion, the patients will be subjected
      to preconditioning treatment. After T cell infusion, the patients will be evaluated for 24
      months for adverse reactions, persistence of CAR T cells and efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor load</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Tumor load will be quantified with radiology, bone marrow and/or blood samples dependent on diagnosis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CAR T cell persistence</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Tumor load will be quantified with radiology, bone marrow and/or blood samples dependent on diagnosis</description>
  </secondary_outcome>
  <other_outcome>
    <measure>B cell number and immunoglobulins in peripheral blood</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>The number of B cells and immunoglobulins in peripheral blood will be evaluated by routine methods</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>B-Cell Leukemia</condition>
  <condition>B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>CD19 CAR T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous CD19-targeting CAR T cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous CD19-targeting CAR T cells</intervention_name>
    <description>Autologous CD19-targeting CAR T cells with three signaling domains derived from CD3zeta, CD28 and 4-1BB.</description>
    <arm_group_label>CD19 CAR T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. The treat history meeting the following criteria:

               -  Recurrence of lymphoma patients with imaging (CT/MRI/PET-CT) detection and
                  pathological diagnosis, or recurrence including bone marrow morphology relapse
                  and the MRD recurrence of myeloma patients or leukemia patients, after
                  chemotherapy or stem cell transplantation;

               -  Can't get complete remission (including MRD positive) after more than twice
                  repeated chemotherapy of incipient lymphoma, myeloma or leukemia patients;

               -  One or twice chemotherapy cannot get remission again (including MRD positive),
                  but not suitable for chemotherapy of incipient lymphoma, myeloma or leukemia
                  patients.

          2. There is a measurable lesions before treatment at least;

          3. ECOG score≤2;

          4. To be aged 1 to 70 years;

          5. More than a month lifetime from the consent signing date

        Exclusion Criteria:

          -  Serious cardiac insufficiency, left ventricular ejection fraction＜50;

          -  Has a history of severe pulmonary function damaging;

          -  Merging other malignant tumor;

          -  Merging uncontrolled infection;

          -  Merging the metabolic diseases (except diabetes);

          -  Merging severe autoimmune diseases or immunodeficiency disease;

          -  patients with active hepatitis B or hepatitis C;

          -  patients with HIV infection;

          -  Has a history of serious allergies on Biological products (including antibiotics);

          -  Happened in 3 ~ 4 acute GvHD after allogeneic hematopoietic stem cell transplantation
             on recurring patients Pregnancy or lactation women; Any situation that would increase
             dangerousness of subjects or disturb the outcome of the clinical study according to
             the researcher's evaluation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianmin Luo, PhD &amp; MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Second Hospital of Hebei Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>jianqiang li, PhD &amp; MD</last_name>
    <phone>+8631189928689</phone>
    <email>limmune@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jianmin Luo, PhD &amp; MD</last_name>
    <phone>+8631166002304</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>No.2 Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianqiang Li, PhD &amp; MD</last_name>
      <phone>+86311-89928689</phone>
      <email>limmune@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Jianmin Luo, PhD &amp; MD</last_name>
      <phone>+86311-66002304</phone>
    </contact_backup>
    <investigator>
      <last_name>Jianmin Luo, PhD &amp; MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jianqiang Li, PhD &amp; MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 28, 2016</study_first_submitted>
  <study_first_submitted_qc>November 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2016</study_first_posted>
  <last_update_submitted>April 27, 2017</last_update_submitted>
  <last_update_submitted_qc>April 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Leukemia, B-Cell</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

